AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics as part of a strategic partnership focused on developing cancer treatments. The investment will give AstraZeneca rights equivalent to about 12% of Summit’s outstanding common stock, or about 10.6% on a fully diluted basis, according to AstraZeneca’s Sept. 29 SEC filing.
The British pharmaceutical company will purchase approximately 109,000 newly issued preferred shares of Summit that are convertible into common stock at a 1-to-1,000 ratio. The transaction values each common-stock equivalent at $18.36 per share. Closing is expected within one week, subject to customary conditions, while any future conversion of the preferred shares into common stock would require customary regulatory clearances.
The investment accompanies a clinical collaboration centered on Summit’s ivonescimab, a bispecific antibody designed to target PD-1 and VEGF. AstraZeneca and Summit plan to evaluate ivonescimab in combination with AstraZeneca’s sonesitatug vedotin, an antibody-drug conjugate targeting CLDN18.2, initially in gastrointestinal cancers.
Under the collaboration, each company will contribute its respective medicine to the planned combination trials and jointly contribute to trial costs. The companies will retain development and commercial rights to their respective medicines rather than combining ownership of the underlying drug programs.
The companies also signed a memorandum of understanding covering a potential broader global development program. That effort is intended to evaluate ivonescimab alongside additional AstraZeneca cancer medicines, including other antibody-drug conjugates.
For Summit, the transaction provides $2 billion of new capital while establishing a strategic relationship with one of the world’s largest pharmaceutical companies. Summit said the investment is intended to accelerate development of ivonescimab and expand combination studies across tumor types.
For AstraZeneca, the deal adds exposure to Summit’s oncology pipeline without an acquisition of the company. AstraZeneca said its broader oncology strategy is focused on using antibody-drug conjugates as a backbone for combinations with next-generation immunotherapies across different cancer types.
Ivonescimab is being developed as a PD-1/VEGF bispecific antibody. Summit holds rights outside Greater China to the medicine, which was developed by Akeso and is being investigated in multiple cancer settings.
The transaction also comes as AstraZeneca continues to expand its oncology portfolio through external partnerships and investments. The company’s latest agreement with Summit combines a significant equity investment with a clinical development program, linking the financial commitment directly to the advancement of cancer therapies.
Summit’s shares rose sharply in premarket trading following the announcement, while AstraZeneca shares also gained in London. The market reaction reflects the immediate significance investors placed on the strategic investment, although the clinical programs remain subject to ongoing development and regulatory review.
